In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List

7th IPF Summit

Sep 19, 2023 - 09:00 AM - Sep 21, 04:00 PM
Hanson Wade
REVERE Hotel Boston Common
200, Stuart St

ZIP: 02116
Phone: +1 617 455 4188

Ticket Price: USD 2599.00 - USD 5297.00

With Nintedanib and Pirfenidone set to lose their patents in the next 3-6 years, Pliant Therapeutics moving into phase 2b, readouts expected from FibroGen's phase 3 trial and Galecto's phase 2 study and Bristol Myers Squibb's and Boehringer Ingelheim's clinical trials both well under way...the race is on to advance the next generation of IPF drugs and beat the benchmark set by the standard of care.

We're at the precipice of hailing disease-modifying IPF drugs to patients with the increasing understanding of lung pathobiology and cell cross talk using multi-omic approaches expanding the horizons of therapeutic targets to slow, halt, reverse and regenerate progressively fibrosing lung tissue. Imaging and AI are being harnessed more than ever to show therapeutic efficacy beyond lung function and clinical trials are being designed to be more effective and swifter.

The 7th IPF Summit is the undisputed, comprehensive, end-to-end, 3-day conference for you and your team to grasp the latest readouts and take new insights back to your therapeutic development. Don't miss this opportunity to discuss the latest unpublished data and network with 180+ movers and shakers in the pulmonary fibrosis field.

Tickets: https://go.evvnt.com/1778010-2?pid=1052
Brochure: https://go.evvnt.com/1778010-3?pid=1052

Drug Developer - Conference + Seminar Day: USD 4297.00,
Drug Developer - Conference Only: USD 2999.00,
Solution Provider - Conference + Seminar Day: USD 5297.00,
Solution Provider - Conference Only: USD 3799.00,
Academic Pricing - Conference + Seminar Day: USD 3697.00,
Academic Pricing - Conference Only: USD 2599.00

Speaker Details

Andrew Thorley, Director, Principal Scientist and Group Leader - Nephrology and Chronic Obstructive Pulmonary Disease and Biomarker Development, Genentech, Bertil Lindmark, Chief Medical Officer, Galecto Biotech, Caroline Owen, Executive Director - Medical Early Clinical Development, Respiratory and Immunology, AstraZeneca, Cathy Swindlehurst, Chief Executive Officer, NovoMedix, Christina Kalderén, Preclinical director, Oxcia, David Lederer, Executive Medical Director, Early Clinical Development and Experimental Sciences, Regeneron, David Salzman, Founder and Chief Executive Officer, GATEHOUSE BIO, Elizabeth Redente, Associate Professor, National Jewish Health, Eric Lefebvre, Chief Medical Officer, Pliant Therapeutics Inc., Eric White, Senior Lead - Clinical Program and Interstitial lung disease, Boehringer Ingelheim, Fernando Martinez, Professor - Internal Medicine, Weill Cornell Medical College, Gary Matt Hunninghake, Assistant Professor, Brigham and Women's Hospital at Harvard Medical School, Gisli Jenkins, Chair and Professor - Research and Margaret Turner Warwick Thoracic Medicine, Imperial College, London, Hans Brightbill, Senior Manager - Scientific and Translational Immunology and Fibrosis Disease Area Strategy Lead, Genentech, Hans-Willem Snoeck, Professor - Medicine, Microbiology and Immunology, Columbia University, Jessica Shore, Vice President of Clinical Affairs and Quality, Pulmonary Fibrosis Foundation, Joyce Lee Associate, Professor - Medicine-Pulmonary Sciences and Critical Care, University of Colorado Anschutz Medical Campus, Justin Oldham, Associate Professor, University of Michigan, Ke Cheng, Professor, Founder (BreStem Therapeutics), NC State University, Kevin Hart, Director and Associate Fellow - Scientific and Research, Pfizer, Lee Borthwick, Chief Operating Officer and Director, FibroFind, Lyn Barinowski, Chief Executive Officer, Avalyn Pharmaceuticals, Mahboobe Ghaedi, Lead Principle Scientist - Respiratory and Inflammation, AstraZeneca, Mark Eisner, Executive Vice President and Chief Medical Officer, FibroGen, Matthew Moll, Instructor in Medicine, Brigham and Women's Hospital at Harvard Medical School, Muhunthan Thillai, Director, Qureight, Muriel Lize, Associate Director - In Vitro Respiratory Research, Boehringer Ingelheim, Naftali Kaminski, Professor and Chief Of Medicine, Section Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, Peter George, Consultant and Clinical Lead Royal Brompton and Harefield, NHS Trust, Philip Zach Brohawn, Head of Biomarker Discovery, AstraZeneca, Rahul Ballal, Chief Executive Officer, Mediar Therapeutics, Robin Mansukhani, Chief Executive Officer, Deciduous Therapeutics, Rohit Batta, Chief Medical Officer, Vicore Pharma Holding, Simon Walsh, Clinician Scientist, Imperial College London, Steven Greenberg, Executive Director - Inflammation and Immunology, Bristol Myers Squibb, Sudha Visvanathan, Vice President, Global Head of Theraputic Area Inflammation, Boehringer Ingelheim, Sunhwa Kim, Associate Scientific Director, Abbvie, Timothy Watkins, Vice President and Head, Fibrosis and Pulmonary Diseases and Inflammation, Gilead Sciences, Toby Maher, Clinical Instructor, University of Southern California, Vanessa Neiens, Biology Lead Respiratory, Pieris Pharmaceuticals

Event Categories
Keywords: science , Conferences


Events Calendar

27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Event Location


VIP Life Time Subscription to our Newsletters!